Cargando…

Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD

OBJECTIVE: During PREVENT (NCT01892345), eculizumab significantly reduced relapse risk versus placebo in patients with aquaporin‐4 immunoglobulin G‐positive neuromyelitis optica spectrum disorder (AQP4‐IgG+ NMOSD). We report an interim analysis of PREVENT's ongoing open‐label extension (OLE; NC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wingerchuk, Dean M., Fujihara, Kazuo, Palace, Jacqueline, Berthele, Achim, Levy, Michael, Kim, Ho Jin, Nakashima, Ichiro, Oreja‐Guevara, Celia, Wang, Kai‐Chen, Miller, Larisa, Shang, Shulian, Sabatella, Guido, Yountz, Marcus, Pittock, Sean J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248139/ https://www.ncbi.nlm.nih.gov/pubmed/33586143 http://dx.doi.org/10.1002/ana.26049

Ejemplares similares

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension
por: Pittock, Sean J, et al.
Publicado: (2021)

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder
por: Berthele, Achim, et al.
Publicado: (2023)

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab
por: Paul, Friedemann, et al.
Publicado: (2023)

Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG–positive NMOSD
por: Shosha, Eslam, et al.
Publicado: (2018)

Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder
por: Wingerchuk, Dean M., et al.
Publicado: (2021)

Adverse Events in NMOSD Therapy
por: Giglhuber, Katrin, et al.
Publicado: (2022)

A Response to: Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”
por: Wingerchuk, Dean M., et al.
Publicado: (2022)

Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan
por: Nakashima, Ichiro, et al.
Publicado: (2023)

Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab
por: Kowarik, Markus C., et al.
Publicado: (2016)

Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD
por: Cree, Bruce AC, et al.
Publicado: (2021)

The aquaporin4-IgG status and how it affects the clinical features and treatment response in NMOSD patients in Egypt
por: Kishk, Nirmeen A., et al.
Publicado: (2021)

Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD
por: Akaishi, Tetsuya, et al.
Publicado: (2020)

CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder
por: Namatame, Chihiro, et al.
Publicado: (2021)

Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD
por: McBride, Helen J., et al.
Publicado: (2023)

CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications
por: Kaneko, Kimihiko, et al.
Publicado: (2018)

Higher longitudinal brain white matter atrophy rate in aquaporin-4 IgG-positive NMOSD compared with healthy controls
por: Masuda, Hiroki, et al.
Publicado: (2023)

Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD
por: Zeka, Bleranda, et al.
Publicado: (2016)

Consistent improvement with eculizumab across muscle groups in myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

Chronic Cognitive Impairment in AQP4+ NMOSD With Improvement in Cognition on Eculizumab: A Report of Two Cases
por: Saab, Georges, et al.
Publicado: (2022)

Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders
por: Palace, Jacqueline, et al.
Publicado: (2019)

Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD
por: Jitprapaikulsan, Jiraporn, et al.
Publicado: (2020)

Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders
por: Redenbaugh, Vyanka, et al.
Publicado: (2021)

Treatment and outcome of aquaporin-4 antibody–positive NMOSD: A multinational pediatric study
por: Paolilo, Renata Barbosa, et al.
Publicado: (2020)

Radiologically isolated syndrome and the possibility of preclinical disease activity in aquaporin-4 antibody NMOSD
por: Rotstein, Dalia L
Publicado: (2022)

Long‐term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses
por: Howard, James F., et al.
Publicado: (2021)

NMO-IgG: A Specific Biomarker for Neuromyelitis Optica
por: Weinshenker, Brian G., et al.
Publicado: (2006)

Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS
por: Zeka, Bleranda, et al.
Publicado: (2015)

NMOSD IgG Impact Retinal Cells in Murine Retinal Explants
por: Wolf, Hannah Nora, et al.
Publicado: (2023)

AQP4-IgG NMOSD, MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance imaging?
por: Fragoso, Diego Cardoso, et al.
Publicado: (2023)

Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
por: Hor, Jyh Yung, et al.
Publicado: (2020)

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
por: Lennon, Vanda A., et al.
Publicado: (2005)

The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD
por: Berhanu, David, et al.
Publicado: (2023)

COVID-19 in a patient treated with eculizumab for aquaporin-4 neuromyelitis optica
por: Cabal-Herrera, Ana Maria, et al.
Publicado: (2021)

Epitope Analysis of Cerebrospinal Fluid IgG in Japanese Multiple Sclerosis Patients Using Phage Display Method
por: Fujimori, Juichi, et al.
Publicado: (2011)

Aquaporin-4 antibody-positive myelitis initially biopsied for suspected spinal cord tumors: Diagnostic considerations
por: Sato, Douglas Kazutoshi, et al.
Publicado: (2013)

Characterization of Disease Severity and Stability in NMOSD: A Global Clinical Record Review with Patient Interviews
por: Capobianco, Marco, et al.
Publicado: (2023)

AQP4‐IgG positive paraneoplastic NMOSD: A case report and review
por: Ding, Manqiu, et al.
Publicado: (2021)

Severe aquaporin 4-IgG-positive neuromyelitis optica with disseminated herpes zoster in a pregnant woman successfully treated with intravenous immunoglobulin
por: Matsumoto, Yuki, et al.
Publicado: (2018)

Lethal form of a late-onset aquaporin-4 antibody-positive NMOSD related to the immune checkpoint inhibitor nivolumab
por: Weiss, David, et al.
Publicado: (2021)

Optic neuritis after ocular trauma in anti‐aquaporin‐4 antibody‐positive neuromyelitis optica spectrum disorder
por: Akaishi, Tetsuya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g2qgov4v6bn442c4jltq32mafu